Growth Metrics

KalVista Pharmaceuticals (KALV) Short-Term Debt repayments (2014)

KalVista Pharmaceuticals recorded quarterly Short-Term Debt repayments of $5.7 million in Q4 2014, up 208.07% quarter-over-quarter from -$5.3 million in Q3 2014.

KalVista Pharmaceuticals' Short-Term Debt repayments history runs 1 years deep, the most recent figure standing at $5.7 million for Q4 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 102,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2014 5.71 Mn
Dec 31, 2014 5.71 Mn
Sep 30, 2014 -5.28 Mn
Sep 30, 2014 -5.28 Mn